Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
Article Abstract:
Intensive chemotherapy plus autologous bone marrow transplantation may be more effective than standard chemotherapy alone in improving survival of patients with relapses of non-Hodgkin's lymphoma. A total of 109 patients with relapses of non-Hodgkin's lymphoma responded to two courses of conventional chemotherapy. Among these patients, 54 received additional conventional chemotherapy and 49 received intensive chemotherapy and a transplantation of their own bone marrow which had been previously harvested. Some patients in both groups also received radiation therapy. During a median follow-up of 63 months, the rate of survival without subsequent events was 46% in the transplant group and 12% in the standard chemotherapy group. After five years, the overall survival was 53% in the transplant group and 32% in the standard chemotherapy group. Patients in the transplant group had a much higher rate of toxic side effects, including various infections, kidney and liver toxicity, and mucositis. Three of these patients died from toxic effects.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Autologous or allogenic bone marrowtransplantation compared with intensive chemotherapy in acute myelogenous leukemia
Article Abstract:
Bone marrow transplantation appears to be more effective at preventing relapse of acute myelogenous leukemia (AML) than standard chemotherapy treatment. Most AML patients enter remission after initial treatment, but almost all eventually suffer a relapse. Of 343 AML patients in remission, 144 who had siblings with compatible bone marrow tissue underwent allogenic bone marrow transplants and 128 with no tissue-compatible siblings underwent autologous transplants. The remaining 104 patients underwent intensive chemotherapy. The projected disease-free survival rate for the allogenic transplant group was 55% at four years, compared to 48% for the autologous transplant group and 30% for the non-transplant group. Many of those in the chemotherapy group who suffered relapses benefitted from bone marrow transplant after the second relapse.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
Article Abstract:
The immunohistochemical methods are used to study the subcellular localization of nucleophosmin (NPM) in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). It is concluded that cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Fetal fibronectin as a market to predict the onset of term labor and delivery. Fetal fibronectin as a selection criterion for induction of term labor
- Abstracts: Ergonomics: show 'good faith.' Get in step with the right footwear. Hearing protection: no noise is good news
- Abstracts: Industry and the ozone hole: time is running out. Lack of support slows Superfund reform. EPA reconsiders dioxins, again